Let’s dig into the relative performance of Tandem Diabetes (NASDAQ:TNDM) and its peers as we unravel the now-completed Q4 healthcare technology earnings season.
A number of stocks fell in the afternoon session after stocks gave back some of the gains from the previous day as the White House clarified the tariffs on imports from China would add up to 145%, while the baseline 10% tariffs remained in place for all countries. This reminded markets that the global trade environment remained volatile, limiting the potential for sustained gains.
What a brutal six months it’s been for Omnicell. The stock has dropped 24.6% and now trades at $32.45, rattling many shareholders. This was partly driven by its softer quarterly results and may have investors wondering how to approach the situation.
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. But speed bumps such as inventory destockings have persisted in the wake of COVID-19,
and over the past six months, the industry has pulled back by 6.3%. This performance is a noticeable divergence from the S&P 500’s 5.1% return.
Healthcare tech company Omnicell (NASDAQ:OMCL) reported Q4 CY2024 results topping the market’s revenue expectations, with sales up 18.6% year on year to $306.9 million. On the other hand, next quarter’s revenue guidance of $260 million was less impressive, coming in 2% below analysts’ estimates. Its non-GAAP profit of $0.60 per share was 2.8% above analysts’ consensus estimates.
